{"protocolSection": {"identificationModule": {"nctId": "NCT00887250", "orgStudyIdInfo": {"id": "2009_580"}, "secondaryIdInfos": [{"id": "MK0954-050"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Study to Investigate the Antihypertensive Efficacy of MK0954", "officialTitle": "A Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan (MK954, DuP753) in Patients With Mild to"}, "statusModule": {"statusVerifiedDate": "2009-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "1991-12"}, "primaryCompletionDateStruct": {"date": "1992-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "1992-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-04-22", "studyFirstSubmitQcDate": "2009-04-22", "studyFirstPostDateStruct": {"date": "2009-04-23", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-05-07", "resultsFirstSubmitQcDate": "2009-05-07", "resultsFirstPostDateStruct": {"date": "2009-06-24", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2009-07-08", "lastUpdatePostDateStruct": {"date": "2009-07-14", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Executive Vice President, Clinical and Quantitative Sciences", "oldOrganization": "Merck & Co., Inc."}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "After a 4 week placebo period, patients were randomized to Placebo or Losartan 50 mg arms, after 6 weeks non-responders were up titrated to 100 mg losartan for the remaining 6 weeks. This study evaluated if losartan is more effective than placebo in lowering sitting diastolic blood pressure and is well tolerated in patients with mild to moderate hypertension."}, "conditionsModule": {"conditions": ["Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 366, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "PLACEBO_COMPARATOR", "description": "Placebo", "interventionNames": ["Drug: Comparator: Placebo"]}, {"label": "2", "type": "EXPERIMENTAL", "description": "Losartan 50 mg for 12 weeks", "interventionNames": ["Drug: losartan potassium"]}, {"label": "3", "type": "EXPERIMENTAL", "description": "Losartan 50 mg titrated to 100 mg after 6 weeks", "interventionNames": ["Drug: Comparator: losartan"]}], "interventions": [{"type": "DRUG", "name": "losartan potassium", "description": "50 mg Losartan (MK0954) tablet taken once daily for 12 weeks.", "armGroupLabels": ["2"], "otherNames": ["MK0954"]}, {"type": "DRUG", "name": "Comparator: losartan", "description": "50 mg tablet of Losartan (MK0954) taken once daily for 6 weeks, Non-responders will then have the dose up titrated to 100 mg for remaining 6 weeks.", "armGroupLabels": ["3"], "otherNames": ["MK0954"]}, {"type": "DRUG", "name": "Comparator: Placebo", "description": "Placebo to Losartan", "armGroupLabels": ["1"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12", "description": "Mean change from baseline in trough (24 hours post dose) SiDBP at Week 12", "timeFrame": "At baseline and at 12 weeks (24 hours post dose)"}], "secondaryOutcomes": [{"measure": "Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 6", "description": "Patients with trough SiDBP \\<90 mm Hg were in Category I, \u226590 but decreased at least 10 mm Hg were in Category II, and \u226590 and decreased less than 10 mm Hg were in Category III.", "timeFrame": "24 hours post dose at Week 6"}, {"measure": "Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 12", "description": "Patients with trough SiDBP \\<90 mm Hg were in Category I, \u226590 but decreased at least 10 mm Hg were in Category II, and \u226590 and decreased less than 10 mm Hg were in Category III.", "timeFrame": "24 hours post dose at Week 12"}, {"measure": "Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 6", "description": "Mean change from baseline in trough (24 hours post dose) SiDBP at Week 6", "timeFrame": "At baseline and at 6 weeks (24 hours post dose)"}, {"measure": "Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 6", "description": "Mean change from baseline in peak (6 hours post dose) SiDBP at Week 6", "timeFrame": "At baseline and at 6 weeks (24 hours post dose)"}, {"measure": "Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12", "description": "Mean change from baseline in peak (6 hours post dose) SiDBP at Week 12", "timeFrame": "At baseline and at 12 weeks (6 hours post dose)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient has been diagnosed with mild to moderate hypertension (SDBP 95-115 mm Hg)\n* Patient has no medical problems or treatments that might effect their blood pressure\n\nExclusion Criteria:\n\n* Pregnant or lactating females\n* Patient has secondary hypertension or malignant hypertension\n* Sitting systolic blood pressure \\> 210 mm Hg\n* History of stroke\n* History of myocardial infarction with in past year\n* Current or prior history of heart failure\n* Known hypersensitivity to losartan\n* Prior exposure to losartan\n* Patients known to be HIV positive\n* Patient is abusing or has abused alcohol or other drugs within the past 4 years", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "21 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Patients could be randomized after the 4-week placebo baseline period if their mean sitting diastolic blood pressure (SiDBP) was 95-115 mm Hg and \u22647 mm Hg from the mean SiDBP after 2 weeks of placebo therapy", "recruitmentDetails": "Patients were recruited at 22 sites in the United States. Prime Therapy Period: December, 1991 to August, 1992.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Losartan placebo orally once daily for 12 weeks"}, {"id": "FG001", "title": "Losartan 50 mg", "description": "Losartan 50 mg orally once daily for 12 weeks"}, {"id": "FG002", "title": "Losartan 50/100 mg", "description": "Losartan orally once daily for 12 weeks, initiated as 50 mg and titrated to 100 mg for nonresponders (SiDBP \u226590 mm Hg) after 6 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "116"}, {"groupId": "FG001", "numSubjects": "127"}, {"groupId": "FG002", "numSubjects": "123"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "98"}, {"groupId": "FG001", "numSubjects": "115"}, {"groupId": "FG002", "numSubjects": "110"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "13"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "7"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Patient uncooperative", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Losartan placebo orally once daily for 12 weeks"}, {"id": "BG001", "title": "Losartan 50 mg", "description": "Losartan 50 mg orally once daily for 12 weeks"}, {"id": "BG002", "title": "Losartan 50/100 mg", "description": "Losartan orally once daily for 12 weeks, initiated as 50 mg and titrated to 100 mg for nonresponders (SiDBP \u226590 mm Hg) after 6 weeks"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "116"}, {"groupId": "BG001", "value": "127"}, {"groupId": "BG002", "value": "123"}, {"groupId": "BG003", "value": "366"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.8", "lowerLimit": "26", "upperLimit": "78"}, {"groupId": "BG001", "value": "53.2", "lowerLimit": "28", "upperLimit": "75"}, {"groupId": "BG002", "value": "55.1", "lowerLimit": "28", "upperLimit": "76"}, {"groupId": "BG003", "value": "54.0", "lowerLimit": "26", "upperLimit": "78"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "45"}, {"groupId": "BG003", "value": "131"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "74"}, {"groupId": "BG001", "value": "83"}, {"groupId": "BG002", "value": "78"}, {"groupId": "BG003", "value": "235"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Caucasian", "categories": [{"measurements": [{"groupId": "BG000", "value": "92"}, {"groupId": "BG001", "value": "104"}, {"groupId": "BG002", "value": "101"}, {"groupId": "BG003", "value": "297"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "16"}, {"groupId": "BG003", "value": "47"}]}]}, {"title": "Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "19"}]}]}, {"title": "Indian", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}]}, {"title": "Oriental", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "2"}]}]}]}, {"title": "Sitting Diastolic Blood Pressure (SiDBP)", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "mm Hg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "101.3", "lowerLimit": "95", "upperLimit": "115"}, {"groupId": "BG001", "value": "102.2", "lowerLimit": "95", "upperLimit": "113"}, {"groupId": "BG002", "value": "102.2", "lowerLimit": "95", "upperLimit": "114"}, {"groupId": "BG003", "value": "101.9", "lowerLimit": "95", "upperLimit": "114"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12", "description": "Mean change from baseline in trough (24 hours post dose) SiDBP at Week 12", "populationDescription": "The primary analysis employed an \"all patients treated\" approach that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "At baseline and at 12 weeks (24 hours post dose)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Losartan placebo orally once daily for 12 weeks"}, {"id": "OG001", "title": "Losartan 50 mg", "description": "Losartan 50 mg orally once daily for 12 weeks"}, {"id": "OG002", "title": "Losartan 50/100 mg", "description": "Losartan orally once daily for 12 weeks, initiated as 50 mg and titrated to 100 mg for nonresponders (SiDBP \u226590 mm Hg) after 6 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "114"}, {"groupId": "OG001", "value": "125"}, {"groupId": "OG002", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.3", "spread": "6.7"}, {"groupId": "OG001", "value": "-7.9", "spread": "7.6"}, {"groupId": "OG002", "value": "-8.6", "spread": "7.7"}]}]}]}, {"type": "SECONDARY", "title": "Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 6", "description": "Patients with trough SiDBP \\<90 mm Hg were in Category I, \u226590 but decreased at least 10 mm Hg were in Category II, and \u226590 and decreased less than 10 mm Hg were in Category III.", "populationDescription": "An \"all patients treated\" approach was employed that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "24 hours post dose at Week 6", "groups": [{"id": "OG000", "title": "Placebo", "description": "Losartan placebo orally once daily for 12 weeks"}, {"id": "OG001", "title": "Losartan 50 mg", "description": "Losartan 50 mg orally once daily for 12 weeks"}, {"id": "OG002", "title": "Losartan 50/100 mg", "description": "Losartan orally once daily for 12 weeks, initiated as 50 mg and titrated to 100 mg for nonresponders (SiDBP \u226590 mm Hg) after 6 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "114"}, {"groupId": "OG001", "value": "125"}, {"groupId": "OG002", "value": "118"}]}], "classes": [{"title": "Category I", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "37"}, {"groupId": "OG002", "value": "37"}]}]}, {"title": "Category II", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "20"}, {"groupId": "OG002", "value": "21"}]}]}, {"title": "Category III", "categories": [{"measurements": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "60"}]}]}]}, {"type": "SECONDARY", "title": "Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 12", "description": "Patients with trough SiDBP \\<90 mm Hg were in Category I, \u226590 but decreased at least 10 mm Hg were in Category II, and \u226590 and decreased less than 10 mm Hg were in Category III.", "populationDescription": "An \"all patients treated\" approach was employed that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "24 hours post dose at Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Losartan placebo orally once daily for 12 weeks"}, {"id": "OG001", "title": "Losartan 50 mg", "description": "Losartan 50 mg orally once daily for 12 weeks"}, {"id": "OG002", "title": "Losartan 50/100 mg", "description": "Losartan orally once daily for 12 weeks, initiated as 50 mg and titrated to 100 mg for nonresponders (SiDBP \u226590 mm Hg) after 6 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "114"}, {"groupId": "OG001", "value": "125"}, {"groupId": "OG002", "value": "118"}]}], "classes": [{"title": "Category I", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "40"}, {"groupId": "OG002", "value": "37"}]}]}, {"title": "Category II", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "24"}]}]}, {"title": "Category III", "categories": [{"measurements": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "67"}, {"groupId": "OG002", "value": "57"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 6", "description": "Mean change from baseline in trough (24 hours post dose) SiDBP at Week 6", "populationDescription": "An \"all patients treated\" approach was employed that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "At baseline and at 6 weeks (24 hours post dose)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Losartan placebo orally once daily for 12 weeks"}, {"id": "OG001", "title": "Losartan 50 mg", "description": "Losartan 50 mg orally once daily for 12 weeks"}, {"id": "OG002", "title": "Losartan 50/100 mg", "description": "Losartan orally once daily for 12 weeks, initiated as 50 mg and titrated to 100 mg for nonresponders (SiDBP \u226590 mm Hg) after 6 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "114"}, {"groupId": "OG001", "value": "125"}, {"groupId": "OG002", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.5", "spread": "5.8"}, {"groupId": "OG001", "value": "-6.9", "spread": "7.0"}, {"groupId": "OG002", "value": "-7.9", "spread": "7.1"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 6", "description": "Mean change from baseline in peak (6 hours post dose) SiDBP at Week 6", "populationDescription": "The primary analysis employed an \"all patients treated\" approach that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "At baseline and at 6 weeks (24 hours post dose)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Losartan placebo orally once daily for 12 weeks"}, {"id": "OG001", "title": "Losartan 50 mg", "description": "Losartan 50 mg orally once daily for 12 weeks"}, {"id": "OG002", "title": "Losartan 50/100 mg", "description": "Losartan orally once daily for 12 weeks, initiated as 50 mg and titrated to 100 mg for nonresponders (SiDBP \u226590 mm Hg) after 6 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "118"}, {"groupId": "OG002", "value": "111"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.1", "spread": "6.9"}, {"groupId": "OG001", "value": "-9.7", "spread": "8.7"}, {"groupId": "OG002", "value": "-8.9", "spread": "8.7"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12", "description": "Mean change from baseline in peak (6 hours post dose) SiDBP at Week 12", "populationDescription": "The primary analysis employed an \"all patients treated\" approach that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "At baseline and at 12 weeks (6 hours post dose)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Losartan placebo orally once daily for 12 weeks"}, {"id": "OG001", "title": "Losartan 50 mg", "description": "Losartan 50 mg orally once daily for 12 weeks"}, {"id": "OG002", "title": "Losartan 50/100 mg", "description": "Losartan orally once daily for 12 weeks, initiated as 50 mg and titrated to 100 mg for nonresponders (SiDBP \u226590 mm Hg) after 6 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "121"}, {"groupId": "OG002", "value": "113"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.7", "spread": "7.9"}, {"groupId": "OG001", "value": "-9.5", "spread": "9.2"}, {"groupId": "OG002", "value": "-10.1", "spread": "8.6"}]}]}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Safety has been reported in the literature."}, "certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Executive Vice President, Clinical and Quantitative Sciences", "organization": "Merck & Co., Inc.", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019808", "term": "Losartan"}], "ancestors": [{"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M21701", "name": "Losartan", "asFound": "Staff", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}